Shots:
AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals’ Bretisilocin for moderate-to-severe major depressive disorder (MDD), currently in clinical development
As per the deal, AbbVie will acquire Gilgamesh’s…
26
